Analysts’ Downgrades for May, 30th (BDSI, BEE, BMO, CA, CBNK, DAN, JBLU, PTRY, REGN, SDT)
BioDelivery Sciences International (NASDAQ:BDSI) was downgraded by analysts at ING Group from a hold rating to a sell rating. The analysts wrote, “BioDelivery Sciences International (BDSI) has been downgraded by TheStreet Ratings from hold to sell. The company’s weaknesses can be seen in multiple areas, such as its disappointing return on equity and poor profit margins.”
Bank of Montreal (TSE:BMO) was downgraded by analysts at RBC Capital from an outperform rating to a sector perform rating. RBC Capital currently has C$77.00 target price on the stock, up from their previous target price of C$76.00.
CA (NYSE:CA) was downgraded by analysts at Zacks from an outperform rating to a neutral rating. The firm currently has $30.00 target price on the stock.
Chicopee Bancorp (NASDAQ:CBNK) was downgraded by analysts at ING Group from a buy rating to a hold rating. The analysts wrote, “Chicopee Bancorp (CBNK) has been downgraded by TheStreet Ratings from buy to hold. Among the primary strengths of the company is its expanding profit margins over time. At the same time, however, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity.”
JetBlue Airways Corp. (NASDAQ:JBLU) was downgraded by analysts at Zacks from an outperform rating to a neutral rating. Zacks currently has $10.00 price target on the stock. Zacks’ analyst wrote, “We downgrade our recommendation on JetBlue Airways from Outperform to Neutral owing to its weak first-quarter 2014 results. Both the top and the bottom line missed the Zacks Consensus Estimate. Increased price competition from rivals, rising pilot compensation and rise in other operating expenses remain major concerns for JetBlue. However, network expansion, cost control and increased focus on differentiated product offerings is expected to drive the company’s performance. We believe the recent slot wins in Reagan Airport in addition to JetBlue’s emphasis on expansion in major growth regions like Boston, Fort Lauderdale, the Caribbean and Latin America, will support future growth. Moreover, elimination of certain long haul flights, fleet re-designing, cost-saving moves and lucrative strategic partnerships are expected to create tailwinds for JetBlue going ahead.”
Pantry (NASDAQ:PTRY) was downgraded by analysts at Zacks from a neutral rating to an underperform rating. They currently have $15.80 target price on the stock.
Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by analysts at Zacks from an outperform rating to a neutral rating. They currently have $322.00 target price on the stock. Zacks’ analyst wrote, “Eylea sales in the U.S. were disappointing in the first quarter of 2014, declining 11% sequentially. Management attributed the soft sales to a decrease in distributor inventory and the inclement weather. The company continues to expect 2014 U.S. Eylea sales in the range of $1.7 billion-$1.8 billion. Key action dates in August and October are coming up this year at Regeneron when the FDA will decide on the approval status of Eylea in the DME and BRVO indications, respectively. Hiccups in the approval process will make it challenging to achieve the 2014 guidance given the soft U.S. Eylea sales in the first quarter. We prefer to adopt a wait and watch stance as to how the year spans out for Regeneron. Consequently, we revert to a Neutral recommendation on the stock.”
Bancorp (NASDAQ:TBBK) was downgraded by analysts at ING Group from a buy rating to a hold rating. The analysts wrote, “Bancorp (TBBK) has been downgraded by TheStreet Ratings from buy to hold. The company’s strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and premium valuation.”
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.